MeSH term
Frequency | Condition_Probility | Adult | 7 | 0.0 |
Amino Acid Sequence | 13 | 0.0 |
Animals | 35 | 0.0 |
Blotting, Western | 2 | 0.0 |
Humans | 54 | 0.0 |
Male | 14 | 0.0 |
Molecular Sequence Data | 14 | 0.0 |
Potassium Channels, Voltage-Gated | 32 | 58.0 |
Precipitin Tests | 3 | 0.0 |
Rats | 16 | 0.0 |
Research Support, Non-U.S. Gov't | 41 | 0.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Transfection | 10 | 0.0 |
Ion Channels/*genetics/metabolism | 2 | 25.0 |
Amino Acid Substitution | 2 | 0.0 |
Cells, Cultured | 9 | 0.0 |
Gene Expression | 3 | 0.0 |
Genes, Dominant/genetics | 3 | 2.0 |
Microinjections | 3 | 1.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Mutation | 8 | 0.0 |
Patch-Clamp Techniques | 11 | 2.0 |
Pedigree | 10 | 0.0 |
Potassium/metabolism | 5 | 4.0 |
Potassium Channels/*genetics/metabolism | 5 | 17.0 |
Protein Structure, Tertiary/physiology | 2 | 1.0 |
Protein Subunits | 2 | 0.0 |
Structure-Activity Relationship | 3 | 0.0 |
Xenopus | 7 | 1.0 |
Epilepsy, Benign Neonatal/genetics | 2 | 66.0 |
Immunohistochemistry | 4 | 0.0 |
Mice | 8 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Organ Specificity | 2 | 0.0 |
Potassium Channels/genetics/*metabolism | 4 | 15.0 |
Research Support, U.S. Gov't, P.H.S. | 12 | 0.0 |
Gene Expression Regulation/genetics | 2 | 1.0 |
Mutation/*genetics | 4 | 0.0 |
Point Mutation | 2 | 0.0 |
Electric Conductivity | 4 | 2.0 |
Electrophysiology | 6 | 1.0 |
Female | 11 | 0.0 |
In Situ Hybridization | 2 | 0.0 |
*Mutation | 6 | 0.0 |
Potassium Channels/*genetics/physiology | 2 | 28.0 |
Xenopus laevis | 4 | 0.0 |
Anticonvulsants/*pharmacology | 2 | 10.0 |
CHO Cells | 7 | 0.0 |
Carbamates/*pharmacology | 2 | 28.0 |
Hamsters | 7 | 0.0 |
Indoles/pharmacology | 7 | 3.0 |
Muscarinic Agonists/pharmacology | 2 | 5.0 |
Phenylenediamines/*pharmacology | 2 | 100.0 |
*Potassium Channels, Voltage-Gated | 13 | 4.0 |
Pyridines/pharmacology | 6 | 2.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Receptor, Muscarinic M1 | 2 | 8.0 |
Ion Channel Gating | 2 | 2.0 |
Brain/cytology/metabolism | 2 | 5.0 |
COS Cells | 3 | 0.0 |
Cell Line | 5 | 0.0 |
Cloning, Molecular | 5 | 0.0 |
Neurons/cytology/drug effects/*metabolism | 2 | 5.0 |
Tetraethylammonium/pharmacology | 4 | 19.0 |
Tissue Distribution | 3 | 0.0 |
Chromosome Mapping | 5 | 0.0 |
Phenotype | 4 | 0.0 |
Chromosomes, Human, Pair 6/genetics | 2 | 1.0 |
DNA Mutational Analysis | 3 | 0.0 |
Infant | 2 | 0.0 |
Infant, Newborn | 9 | 0.0 |
Potassium Channels/*genetics | 8 | 6.0 |
Ion Transport | 2 | 2.0 |
*Point Mutation | 2 | 0.0 |
Base Sequence | 4 | 0.0 |
Japan | 2 | 0.0 |
Polymerase Chain Reaction | 4 | 0.0 |
Seizures/congenital/*genetics | 2 | 66.0 |
Sequence Alignment | 3 | 0.0 |
Potassium Channels/*physiology | 3 | 10.0 |
Neurons/*physiology | 2 | 1.0 |
Variation (Genetics) | 2 | 0.0 |
Epilepsy/*genetics | 2 | 6.0 |
Anthracenes/pharmacology | 2 | 10.0 |
English Abstract | 3 | 0.0 |
Potassium Channels/genetics | 4 | 8.0 |
*Chromosome Mapping | 2 | 0.0 |
Electroencephalography | 3 | 1.0 |
Epilepsy, Generalized/*genetics | 3 | 10.0 |
Linkage (Genetics) | 3 | 0.0 |
Myoclonic Epilepsy, Juvenile/*genetics | 2 | 18.0 |
Benzimidazoles/pharmacology | 2 | 4.0 |
Kinetics | 3 | 0.0 |
Membrane Potentials/drug effects/physiology | 2 | 2.0 |
Sulfanilamides/pharmacology | 2 | 100.0 |
Adolescent | 3 | 0.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Genotype | 2 | 0.0 |
Middle Aged | 3 | 0.0 |
DNA Primers | 2 | 0.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
Potassium Channel Blockers/pharmacology | 4 | 13.0 |
Brain/metabolism | 3 | 0.0 |
Oocytes | 3 | 2.0 |
Ion Channel Gating/physiology | 3 | 13.0 |
Aged | 2 | 0.0 |
Child | 2 | 0.0 |
Epilepsy, Benign Neonatal/*genetics | 3 | 50.0 |
Comparative Study | 3 | 0.0 |
Neurons/drug effects/*physiology | 2 | 6.0 |
Potassium/pharmacology | 2 | 3.0 |
Potassium Channels/chemistry/*physiology | 2 | 100.0 |
Hela Cells | 2 | 0.0 |
Rats, Wistar | 2 | 0.0 |
Oocytes/metabolism | 3 | 1.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
